Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48)
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)
Sponsor: Daiichi Sankyo
Listed as NCT00781391, this PHASE3 trial focuses on Atrial Fibrillation and Embolism and remains completed. Sponsored by Daiichi Sankyo, it has been updated 11 times since 2008, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
- The TIMI Study Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aarhus N, Denmark , Abbeville, France , Adana, Turkey (Türkiye) , Adelaide, Australia , Afula, Israel , Aguascalientes, Mexico , Ahmedabad, India , Aichi, Japan , Ajax, Canada and 985 more locations